---
title: "AstraZeneca Reports Mixed Lung Cancer Trial Outcomes From Three Pivotal Studies"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296114723.md"
description: "AstraZeneca reported mixed results from three pivotal lung cancer trials. Tagrisso combined with Orpathys showed significant survival benefits in the SAFFRON study, while Enhertu demonstrated substantial progression-free survival improvements in the DESTINY-Lung04 trial. Conversely, AstraZeneca halted the eVOLVE-Lung02 Phase 3 study for volrustomig due to likely failure to meet primary endpoints in PD-L1-negative patients. Other volrustomig studies will continue."
datetime: "2026-08-17T13:16:54.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296114723.md)
  - [en](https://longbridge.com/en/news/296114723.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296114723.md)
generator: "portal-rs"
---

# AstraZeneca Reports Mixed Lung Cancer Trial Outcomes From Three Pivotal Studies

**AstraZeneca Plc** (NYSE:AZN) on Monday reported a mix of clinical trial outcomes for its lung cancer treatments, achieving notable successes in two late-stage trials while discontinuing a third study due to missed primary endpoints.

## Favorable Results For Targeted Therapies

In the SAFFRON Phase 3 study, the combination of Tagrisso and Orpathys delivered a clinically meaningful and statistically significant extension in both overall survival and progression-free survival (PFS) against standard platinum-based chemotherapy.

This trial focused on patients with epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) who experienced disease progression after earlier Tagrisso therapy.

 **Read Also: AstraZeneca-Bristol Myers Merger Buzz Puts Patent Expiration and Deal Economics in Focus** 

According to the data, these patients exhibited high MET amplification or overexpression, a frequent resistance mechanism associated with a poor prognosis.

The safety profile remained consistent with prior studies, and findings will be shared with global regulatory bodies.

Orpathys is co-developed by AstraZeneca and **HUTCHMED Ltd** (NASDAQ:HCM).

The DESTINY-Lung04 Phase 3 trial yielded encouraging results for Enhertu as a primary treatment for unresectable, locally advanced, or metastatic HER2-mutant non-squamous NSCLC.

The engineered antibody-drug conjugate, jointly developed with Daiichi Sankyo, demonstrated substantial PFS improvements over the global standard of care.

## Discontinuation of eVOLVE-Lung02 Study

On Monday, AstraZeneca said it is halting the eVOLVE-Lung02 Phase 3 trial.

The study assessed volrustomig combined with chemotherapy as an initial therapy for metastatic NSCLC patients exhibiting PD-L1 expression below 50%.

Following a scheduled review, the Independent Data Monitoring Committee determined the combination would likely fall short of its dual primary endpoints in the PD-L1-negative patient cohort.

Consequently, the trial is ending, though no unexpected safety signals emerged.

Meanwhile, other Phase 3 volrustomig evaluations targeting mesothelioma, cervical cancer, and head and neck squamous cell carcinoma will proceed as scheduled.

**AZN Stock Price Activity**: AstraZeneca shares were up 0.20% at $156.76 during premarket trading on Monday, according to Benzinga Pro data.

 **Read Also: Why Sandisk Bulls Think the Old Memory Boom-And-Bust Playbook Is Dead** 

*Photo by Piotr Swat via Shutterstock*

### Related Stocks

- [AZN.US](https://longbridge.com/en/quote/AZN.US.md)
- [AZN.UK](https://longbridge.com/en/quote/AZN.UK.md)
- [HCM.US](https://longbridge.com/en/quote/HCM.US.md)
- [4568.JP](https://longbridge.com/en/quote/4568.JP.md)
- [DSNKY.US](https://longbridge.com/en/quote/DSNKY.US.md)
- [SNDK.US](https://longbridge.com/en/quote/SNDK.US.md)
- [00013.HK](https://longbridge.com/en/quote/00013.HK.md)

## Related News & Research

- [AstraZeneca halts lung cancer trial of volrustomig in latest blow to pipeline](https://longbridge.com/en/news/296069146.md)
- [AstraZeneca: Tagrisso Plus Orpathys Phase III Trial Shows PFS, OS Improvements In EGFRm Lung Cancer](https://longbridge.com/en/news/296071807.md)
- [REG - AstraZeneca PLC - Update on eVOLVE-Lung02 Phase III trial](https://longbridge.com/en/news/296062318.md)
- [CSPC Innovation Pharmaceutical: Biopharma licensing and product launches drove record revenue and profit growth](https://longbridge.com/en/news/296129143.md)
- [AstraZeneca held talks with Bristol-Myers through spring, summer - FT](https://longbridge.com/en/news/295571239.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**